PD-L1 and CD58 co-regulated by CMTM6 play yin and yang to shape anti-tumor immunity
Cancer Cell · 2023
DOI: 10.1016/j.ccell.2023.08.009 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancer Cell, 2023. Verfasst von Hirohito Yamaguchi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Sciences and Institute of Biochemistry and Molecular Biology, China Medical University, Taichung City 406040, Taiwan…. Hauptthemen laut MEDLINE: MARVEL Domain-Containing Proteins, B7-H1 Antigen, CD58 Antigens, Neoplasms. Die Arbeit nennt 10 Literaturangaben. Gefördert von: Ministry of Education, National Science and Technology Council, China Medical University.
Abstract (Originalsprache)
The CD58-CD2 axis regulates T cell-mediated cancer immunity, but little is known about the regulation of CD58. In two recent papers pubished in Cancer Cell, Miao et al. and Ho et al. define a mechanism of CD58 regulation by CMTM6 and show an unexpected yin-yang link between PD-L1 and CD58.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Biomedical Sciences and Institute of Biochemistry and Molecular Biology, China Medical University, Taichung City 406040, Taiwan; Center for Molecular Medicine, China Medical University Hospital, Ta…
Förderung
- Ministry of Education
- National Science and Technology Council
- China Medical University
- Ministry of Health and Welfare
Zitieren
APA
Yamaguchi, H., & Hung, M. C. (2023). PD-L1 and CD58 co-regulated by CMTM6 play yin and yang to shape anti-tumor immunity. Cancer Cell. https://doi.org/10.1016/j.ccell.2023.08.009
Vancouver
Yamaguchi H, Hung MC. PD-L1 and CD58 co-regulated by CMTM6 play yin and yang to shape anti-tumor immunity. Cancer Cell. 2023. doi:10.1016/j.ccell.2023.08.009
BibTeX
@article{Yamaguchi2023,
author = {Yamaguchi, Hirohito and Hung, Mien-Chie},
title = {PD-L1 and CD58 co-regulated by CMTM6 play yin and yang to shape anti-tumor immunity},
journal = {Cancer Cell},
year = {2023},
doi = {10.1016/j.ccell.2023.08.009}
}
EUVIMED